Market Cap
US$403.9m
Last Updated
2019/11/19 00:44 UTC
Data Sources
Company Financials +
Executive Summary
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally.
Snowflake
Fundamentals
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Ardelyx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARDX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.1%
ARDX
1.1%
US Biotechs
0.9%
US Market
1 Year Return
126.9%
ARDX
9.1%
US Biotechs
15.5%
US Market
Return vs Industry: ARDX exceeded the US Biotechs industry which returned 9.1% over the past year.
Return vs Market: ARDX exceeded the US Market which returned 15.5% over the past year.
Shareholder returns
| ARDX | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.1% | 1.1% | 0.9% |
| 30 Day | 42.0% | 10.4% | 4.7% |
| 90 Day | 87.2% | 5.8% | 6.6% |
| 1 Year | 126.9%126.9% | 10.1%9.1% | 18.1%15.5% |
| 3 Year | -57.8%-57.8% | 16.0%12.3% | 48.0%38.5% |
| 5 Year | -73.2%-73.2% | 4.5%-0.4% | 62.1%44.2% |
Price Volatility Vs. Market
How volatile is Ardelyx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Health Check: How Prudently Does Ardelyx (NASDAQ:ARDX) Use Debt?1 month ago | Simply Wall St
Did Changing Sentiment Drive Ardelyx's (NASDAQ:ARDX) Share Price Down A Painful 81%?1 month ago | Simply Wall St
Could Ardelyx, Inc.'s (NASDAQ:ARDX) Investor Composition Influence The Stock Price?Valuation
Is Ardelyx undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARDX ($6.42) is trading below our estimate of fair value ($14.65)
Significantly Below Fair Value: ARDX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARDX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ARDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARDX is overvalued based on its PB Ratio (8.2x) compared to the US Biotechs industry average (2.8x).
Next Steps
Future Growth
How is Ardelyx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
53.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARDX's revenue (79% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: ARDX's revenue (79% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARDX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Ardelyx performed over the past 5 years?
-28.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARDX has high quality earnings.
Growing Profit Margin: ARDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARDX is unprofitable, and losses have increased over the past 5 years at a rate of -28.7% per year.
Accelerating Growth: Unable to compare ARDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).
Return on Equity
High ROE: ARDX has a negative Return on Equity (-209.55%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Ardelyx's financial position?
Financial Position Analysis
Short Term Liabilities: ARDX's short term assets ($110.8M) exceeds its short term liabilities ($17.7M)
Long Term Liabilities: ARDX's short term assets ($110.8M) exceeds its long term liabilities (52.6M)
Debt to Equity History and Analysis
Debt Level: ARDX's debt to equity ratio (101.3%) is considered high.
Reducing Debt: Insufficient data to determine if ARDX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: ARDX has a low level of unsold assets or inventory.
Debt Coverage by Assets: ARDX's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ARDX has sufficient cash runway for 1.142348 years if free cash flow continues to grow at historical rates of 11.9% each year.
Next Steps
Dividend
What is Ardelyx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ARDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ARDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Ardelyx's salary, the management and board of directors tenure and is there insider trading?
5.5yrs
Average management tenure
CEO
Mike Raab (54yo)
10.7yrs
Tenure
US$4,182,246
Compensation
Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019. Mr. Raab was a V ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD4.18M) is above average for companies of similar size in the US market ($USD1.73M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Management Age and Tenure
5.5yrs
Average Tenure
55yo
Average Age
Experienced Management: ARDX's management team is seasoned and experienced (5.5 years average tenure).
Board Age and Tenure
4.6yrs
Average Tenure
54yo
Average Age
Experienced Board: ARDX's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Senior Key Executive Chief Development Officer |
| Shares | 2,856 |
| Max Price | US$2.54 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 10,054 |
| Max Price | US$2.54 |
| Entity | Individual |
| Role | Chief Legal Officer Executive VP |
| Shares | 2,520 |
| Max Price | US$2.54 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Treasurer |
| Shares | 3,357 |
| Max Price | US$2.55 |
| Entity | Individual |
| Role | Senior Key Executive Chief Development Officer |
| Shares | 6,386 |
| Max Price | US$1.70 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 19,644 |
| Max Price | US$1.70 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Treasurer |
| Shares | 6,556 |
| Max Price | US$1.70 |
| Entity | Individual |
| Role | Chief Legal Officer Executive VP |
| Shares | 4,920 |
| Max Price | US$1.70 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.
Management Team
Mike Raab (54yo)
President
- Tenure: 10.7yrs
- Compensation: US$4.18m
Liz Grammer (55yo)
Executive VP
- Tenure: 5.5yrs
- Compensation: US$1.69m
Mark Kaufmann (51yo)
CFO & Treasurer
- Tenure: 5.5yrs
- Compensation: US$799.18k
David Rosenbaum (58yo)
Chief Development Officer
- Tenure: 4.8yrs
- Compensation: US$1.71m
Rob Blanks
Senior Vice President of Regulatory Affairs & Quality Assurance
- Tenure: 0yrs
Jeff Jacobs (56yo)
Senior Vice President of Technical Operations
- Tenure: 4.8yrs
Dan Olmstead
Vice President of Payer Access
- Tenure: 0yrs
Kimia Keshtbod
Manager of Corporate Communications & Investor Relations
- Tenure: 0yrs
Karen Harrigan
Senior Director Market Development
- Tenure: 0yrs
Dan Pavicich
Senior Director of Market Development
- Tenure: 0yrs
Board Members
Dave Mott (54yo)
Independent Chairman
- Tenure: 5.7yrs
- Compensation: US$127.21k
Gordon Ringold (68yo)
Independent Director
- Tenure: 5.4yrs
- Compensation: US$91.21k
Rob Bazemore (51yo)
Independent Director
- Tenure: 3.4yrs
- Compensation: US$90.71k
Bill Bertrand (54yo)
Independent Director
- Tenure: 4.1yrs
- Compensation: US$93.21k
Jan Lundberg (65yo)
Independent Director
- Tenure: 1.7yrs
- Compensation: US$177.50k
Mike Raab (54yo)
President
- Tenure: 10.7yrs
- Compensation: US$4.18m
Rick Rodgers (52yo)
Independent Director
- Tenure: 5.7yrs
- Compensation: US$110.71k
Geoff Block (53yo)
Independent Director
- Tenure: 0.7yrs
Annalisa Jenkins (54yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: US$97.21k
Company Information
Ardelyx, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Ardelyx, Inc.
- Ticker: ARDX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$403.870m
- Shares outstanding: 62.91m
- Website: https://www.ardelyx.com
Number of Employees
Location
- Ardelyx, Inc.
- 34175 Ardenwood Boulevard
- Suite 200
- Fremont
- California
- 94555
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ARDX | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jun 2014 |
| 41X | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2014 |
Biography
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company’s lead product candidat ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/19 00:44 |
| End of Day Share Price | 2019/11/18 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.